| Autor: |
Fu Q; Department of Biopharmaceutics, School of Pharmacy, No. 103 of Wenhua Road, Shenyang 110016, PR China., Sun J, Zhang W, Sui X, Yan Z, He Z |
| Jazyk: |
angličtina |
| Zdroj: |
Recent patents on anti-cancer drug discovery [Recent Pat Anticancer Drug Discov] 2009 Nov; Vol. 4 (3), pp. 262-72. |
| DOI: |
10.2174/157489209789206869 |
| Abstrakt: |
Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab) paclitaxel (nab-paclitaxel; Abraxane) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nab-technology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
